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Background: Survivors of a cardiac arrest frequently have cognitive and emotional problems and their quality of
life is at risk. We developed a brief nursing intervention to detect cognitive and emotional problems, provide in-
formation and support, promote self-management, and refer them to specialised care if necessary. This study ex-
amined its effectiveness.
Methods:Multicentre randomised controlled trial with measurements at two weeks, three months and twelve
months after cardiac arrest. 185 adult cardiac arrest survivors and 155 caregivers participated. Primary outcome
measureswere societal participation and quality of life of the survivors at one year. Secondary outcomeswere the
patient's cognitive functioning, emotional state, extended daily activities and return to work, and the caregiver's
well-being. Data were analysed using ‘intention to treat’ linear mixed model analyses.
Results: After one year, patients in the intervention group had a signiﬁcantly better quality of life on SF-36 do-
mains Role Emotional (estimated mean differences (EMD) = 16.38, p = 0.006), Mental Health (EMD = 6.87,
p = 0.003) and General Health (EMD = 8.07, p = 0.010), but there was no signiﬁcant difference with regard
to societal participation. On the secondary outcome measures, survivors scored signiﬁcantly better on overall
emotional state (HADS total, EMD = −3.25, p = 0.002) and anxiety (HADS anxiety, EMD = −1.79, p =
0.001) at one year. Furthermore, at three months more people were back at work (50% versus 21%, p =
0.006). No signiﬁcant differences were found for caregiver outcomes.
Conclusion: The outcomes of cardiac arrest survivors can be improved by an intervention focused on detecting
and managing the cognitive and emotional consequences of a cardiac arrest.
Trial registration: Current controlled trials, ISRCTN74835019.© 2015 Elsevier Ireland Ltd. All rights reserved.1. Introduction
Of those people who survive a cardiac arrest, about half suffer cogni-
tive impairments and quality of life can be at risk for all of them [1–3].
The cognitive impairments arise from hypoxic–ischaemic brain injuryability and freedom from bias of
pertise in Rehabilitation and
Netherlands.
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.[4]. Emotional problems, such as anxiety and depression, are also fre-
quently seen, as well as a reduced level of participation in society and
a low return towork rate [5,6]. Caregiversmay also feel highly burdened
and they often have emotional problems, including symptoms of post-
traumatic stress [7,8]. Because a cardiac arrest can affect patients and
caregivers on all these domains, there is an urgent need for an effective
intervention that guides patient and caregiver after survival of a cardiac
arrest.
Although cognitive impairments are common after cardiac arrest
and affect quality of life, these problems often remain undetected by
health care professionals [9,10].We therefore developed a new early in-
tervention service for survivors and their caregivers called ‘Stand still…,
and move on’.
9V.R.M. Moulaert et al. / International Journal of Cardiology 193 (2015) 8–16This brief intervention is directed at screening for cognitive and
emotional problems, provision of information and support, promo-
tion of self-management, and referral to specialised care if necessary
[11].
The goal of this study was to evaluate the effectiveness of this new
intervention for cardiac arrest survivors and their caregivers. We ex-
pected that the intervention would primarily result in a higher level of
participation in society and better quality of life for the survivors and,
in addition, would also improve the well-being of caregivers, compared
with those who had only received usual care. We did not expect the in-
tervention to affect cognitive impairments, as it did not include cogni-
tive training.
2. Methods
2.1. Design overview
This study, named ‘Activity and Life after Survival of a Cardiac Arrest’
(ALASCA), was a multicentre single blind randomised controlled trial in
which we compared the effect of receiving the new intervention along-
side usual care to care as usual only. The study was registered in a trial
register [ISRCTN74835019], and the protocol has been published [12].
Therewere onlyminor deviations from the protocol, which are reported
in the following text.
2.2. Setting
Patients were recruited from the coronary care units and intensive
care units of ﬁve hospitals in the southern part of the Netherlands, be-
tween April 2007 and December 2010. The participating hospitals
serve approximately one million inhabitants. All the hospitals had
protocols for care of resuscitation patients in line with international
guidelines and performed therapeutic hypothermia and pacemaker im-
plantations [13]. In addition, two of the hospitals undertook percutane-
ous coronary interventions, implantable cardioverter deﬁbrillator (ICD)
implantations, catheter ablations, and coronary artery bypass grafts.
Throughout the study period, medical care for cardiac arrest patients
in the participating hospitals remained unchanged.
2.3. Participants
Inclusion criteria for the study were survival more than two weeks
after an in-hospital or out-of-hospital cardiac arrest, living within
50kmof one of theparticipatinghospitals, age 18 years or older and suf-
ﬁcient knowledge of the Dutch language. Exclusion criteria were a life
expectancy of less than threemonths (as estimated by the treating phy-
sician) and living in residential or institutional care prior to the cardiac
arrest.
In this study, we deﬁned caregiver as a partner, spouse or signiﬁcant
other who was closely related to the patient. There were no additional
inclusion or exclusion criteria for the caregivers. If a patient had a part-
ner or a spouse, that personwas asked to participate in the trial together
with the patient. If the patient did not have a partner or a spouse, we
asked the patient to assign another person as the caregiver, but this
was not obligatory.
2.4. Procedure
Newly admitted survivors of cardiac arrest were assessed for
study eligibility and potential participants were approached be-
tween three and ten days after their cardiac arrest. Patients and care-
givers who decided to participate signed an informed consent form.
If the patient did not have the capacity to consent, the caregiver
was asked for provisional consent until the patient had the capacity
to decide.Baseline measurements were planned two weeks after the cardiac
arrest, with follow-up at three and twelve months (main study end
point). At baseline, we also assessed the patient's level of daily function-
ing and participation in society prior to the cardiac arrest. Research
assistants visited the patients at their homes to perform the measure-
ments. The Medical Ethics Committee of Maastricht University Medical
Centre approved the study protocol.
2.5. Randomisation
Participantswere randomly assigned to either the intervention group
or the control group, with a 1:1 allocation ratio. Randomisation took
place after the baseline measurements. The randomisation procedure
was performed centrally by the project leader using a computerised
block randomisation containing blocks of 15. The randomisation scheme
included stratiﬁcation on two variables: hospital site and location of the
cardiac arrest (in-hospital versus out-of-hospital).
Research assistants administered the assessments and were blinded
for group allocation. To check the success of the blinding, they were
asked to indicate group allocation for all participants who completed
the trial, choosing one of the following options: ‘Intervention group’,
‘Control group’ or ‘I don't know’.
2.6. Intervention
In addition to usual health care, patients in the intervention group
received an early intervention named ‘Stand still …, and move on’.
This intervention is a short, individualised, semi-structured intervention
for survivors of cardiac arrest and their caregivers. Table 1 describes
the content and characteristics of the intervention. More details
about the rationale and content of the intervention, as well as
training of the nurses, have been published previously [11]. Further-
more, a process evaluation has found the intervention to be feasible
[14].
2.7. Standard care
This new early intervention was set in the context of and added to
standard care. All participating hospitals had general outpatient cardiac
rehabilitation programmes in which patients could enrol at their cardi-
ologists' discretion [20]. However, there were no speciﬁc programmes
for cardiac arrest survivors and standard care did not include any specif-
ic attention to cognitive impairments.
2.8. Outcomes and follow-up
Table 2 describes themeasurement instruments that were used. Pri-
mary outcomemeasures were the patient's participation in society and
quality of life one year after the cardiac arrest. Secondary outcomemea-
sures were the patient's level of cognitive functioning, emotional state,
extended daily activities and return to work, as well as the caregiver's
quality of life, strain and the emotional state. We assessed all the out-
come measures for the effect evaluation three times: at two weeks
(baseline), threemonths and twelvemonths (endpoint) after the cardi-
ac arrest. More details about the administered measurement instru-
ments can be found in the study protocol [12].
‘Work situation’ was a socio-demographic variable in the proto-
col, but since return to work is an important variable reﬂecting soci-
etal participation, it is now reported as a secondary outcome
measure. ‘Return to work’ was deﬁned as partial or complete return
to a paid job.
The EuroQol 6D was administered as a cost-effectiveness study pa-
rameter and is therefore not included in this effect evaluation.
At baseline, we recorded socio-demographic and medical variables
together with some measures of functioning (left ventricular ejection
Table 1
Content and characteristics of the intervention.
Target group Survivors of cardiac arrest and their caregivers
Main elements 1. Screening for cognitive and emotional problems
2. Provision of support and information on cardiac ar-
rest and possible neurological consequences
3. Promotion of self-management strategies
4. Referral to specialised care if indicated
Obligatory topics —
with examples
1. Cognitive changes and challenges
– Consequences of hypoxic-ischaemic brain injury
– Possible cognitive changes and fatigue
– Advice on how to deal with cognitive problems
2. Emotional changes and challenges
– Possible emotional changes (e.g., anxiety,
depression, fear of recurrence)
– Social isolation, loneliness and loss
– Caregiver strain
– Advice on how to deal with emotional problems
3. Principles of self-management
– Explanation of the principles of self-management
– Practising self-management techniques
Optional topics – Cardiac topics
– Physical changes and challenges
– Activities of daily living
– Changes and challenges for the caregiver
– Partner relationships and sexuality
– Dealing with healthcare providers
– Any other questions from patients or caregivers
Written information – A special information booklet was provided to all
participantsa
– Pre-existing brochures about cardiac and neuro-
logical topics were offered as needed
Available screening
instruments
(not obligatory)
1. Cognitive screening
– Checklist Cognition and Emotion [15]
– Cognitive Log [16]
2. Emotional screening
– Hospital Anxiety and Depression Scale [17]
– Impact of Event Scale [18]
3. Screening for caregiver strain
– Caregiver Strain Index [19]
Providers of
intervention
Specialised nurses with experience in the ﬁeld of
cardiology, neurology or rehabilitation medicine
Start intervention Soon after discharge from the hospital, preferably within
one month
Frequency Between one and six face-to-face consultations
Duration of
consultations
First session: 1 h
Follow-up sessions: 30 min
Telephone consultations are optional.
Location Home visits or out-patient clinic
a Available as additional online ﬁle.
Table 2
Primary and secondary outcome measures.
Outcome
measures
Measurement instrument Range questionnaire
Min (poor)–max
(good)
Primary
Participation in
society
Community Integration
Questionnaire [23]
0–29
Quality of life Short-Form-36 (SF-36), 8
subdomains [24]
EuroQol VAS [25]
0–100
0–100
Secondary
Cognitive
functioning
Cognitive Log [16]
Adult Memory and Information
Processing Battery [26]
Verbal ﬂuency [27]
Trail Making Test A + B [28]
Paragraph recall direct + delayed [29]
Cognitive Failures Questionnaire [30]
0–30
0–~a
0–~a
0–~a
0–21
100–0
Emotional functioning Hospital Anxiety and Depression
Scale (HADS) Total [17]
– Subscale Anxiety
– Subscale Depression
Impact of Event Scale [31]
42–0
21–0
21–0
75–0
Extended daily
activities
Frenchay Activity Index [32] 0–45
Caregiver strain Caregiver Strain Index [19] 13–0
a There is no formal end score.
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Index [22]).2.9. Sample size and power calculation
Scores on the Community Integration Questionnaire (CIQ) were
used to determine an optimal sample size. Since no studies on survivors
of cardiac arrest using this outcomemeasure were available at the start
of the study, we used the scores of patients with traumatic brain injury
whichwere used as a reference value (mean 16.09 (SD 4.20)) [33]. Sam-
ple size calculation (independent-samples t-test, one-sided testing),
with an assumed clinical relevant difference between groups of atleast 10%, an alpha of 0.05 and a power (1 − β) of 0.8, showed that
each group needed 84 patients, resulting in a target sample size of 168
patients. With an estimated 15% loss to follow-up, we aimed to include
200 participants.2.10. Statistical analysis
To check for selection bias, we compared baseline characteristics
(age and gender) of compliant and non-compliant patients. To check
for the selective dropout of participants, we examined the differences
between participants who completed the trial and dropouts on the fol-
lowing baseline characteristics: age, gender, initial overall cognitive sta-
tus, basic activities of daily living and caregiver strain. Group differences
were studied using an independent-samples t-test (continuous vari-
ables with normal distribution), a Mann–Whitney U-test (continuous
variables with non-normal distribution) or a Chi-square test (dichoto-
mous variables).
To investigate effectiveness, we performed linearmixedmodel anal-
yses according to the intention to treat principle, with the primary and
secondary outcome measures as dependent variables. The following
variables were entered as ﬁxed terms: hospital, location of cardiac ar-
rest, time and the interaction term group ∗ time. We assumed an un-
structured covariance structure for the repeated measures, used a
restricted maximum likelihood estimation was and based signiﬁcance
on likelihood ratio tests. Linearmixedmodel analyses replacedmultiple
regression analysis (as was described in the protocol), as this is a
more advanced statistical technique with the following advantages:
it is more suitable for repeated measures as it considers baseline
level and correlation between repeated measures, and patients
who drop out are included in the analysis (assuming the data to be
missing at random).
We separately analyseddifferences in the proportions of peoplewho
had returned to work at three and twelve months using a Chi-square
test.
Additionally, we performed per protocol analyses, incorporating
only those patients in the intervention group who had received the
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analyses.
As we tested multiple primary and secondary outcome measures a
p ≤ 0.01 (two-sided) was considered statistically signiﬁcant. Effect
sizes were reported as estimatedmean differences. Effects were consid-
ered clinically relevant only if the estimated mean difference indicated
an improvement of 10% or more compared with the observed mean in
the control group. Statistical analyses were performed using IBM SPSS
Statistics for Windows, version 21.0.3. Results
3.1. Participants
Fig. 1 presents the ﬂow of participants through the study. Overall,
185 patients were included in the study, of whom 143 (77%) completed
the trial. Patient recruitment took longer than expected, leading us to ex-
tend of the end of the recruitment period from April 2010 to December
2010.
The group of patients who refused to participate was signiﬁcantly
older (mean 67 (SD 12) years versus 60 (SD 12) years, p b 0.001), and
had a signiﬁcantly lower percentage of males (69% versus 83%, p =
0.007). There were no signiﬁcant differences between participants
who dropped out during the trial and those who completed it.
We performed baseline assessments at a median of 24 days after the
cardiac arrest (range 9–70 days), with three- and twelve-month follow-Fig. 1. Flow of participantup assessments at a median of 96 days (range 74–162) and 369 days
(range 353–471), respectively. Table 3 shows the patients' baseline
characteristics.
In addition to the 185 patients, 155 caregivers participated in the
study. They were related to the patients either as a spouse/partner
(n = 138, 89%), child (n = 8, 5%), parent (n = 2, 1%), sibling (n = 4,
3%) or friend/other (n = 3, 2%). Caregivers had a mean age of 55 years
(SD 12) and 134 (86%) were female.3.2. Effects of the intervention
Table 4 presents the effects of the intervention. At baseline, there
were no signiﬁcant differences between the intervention and control
groups. At 12months, there were no signiﬁcant differences with regard
to participation in society, but there were signiﬁcant differences in esti-
matedmeans at 12months in favour of the intervention group on three
domains of quality of life on the SF-36: Role Emotional (p = 0.006),
Mental Health (p = 0.003) and General Health (p = 0.010). Estimated
mean differences improved by 24%, 9% and 13%, respectively, compared
with observed means in the control group.
On the secondary outcomemeasures, we found signiﬁcant improve-
ments at 12 months on overall emotional state (HADS total score, p =
0.002) and anxiety (HADS anxiety subscale, p= 0.001), with estimated
mean differences 40% and 43% higher, respectively, compared to ob-
served means in the control group. Return to work at three months
was signiﬁcantly higher in the intervention group: 24 people (50%)s through the study.
Table 3
Baseline characteristics patients.
Intervention
n = 97
Control
n = 88
n n (%) or mean (SD)
or median (range)
n n (%) or mean (SD)
or median (range)
Socio-demographic variables
Male, n (%) 97 80 (83%) 88 74 (84%)
Age, at cardiac arrest, years 97 60 (12) 88 60 (12)
Marital status 90 88
Married/living with
partner
78 (87%) 71 (84%)
Single/divorced/widowed 12 (13%) 14 (16%)
Highest level of education 91 85
Basic education 37 (41%) 35 (41%)
Further education 29 (32%) 29 (34%)
Higher education 25 (27%) 21 (25%)
Employment status,
premorbid
91 84
Paid job 44 (48%) 45 (54%)
Retired/disability pension 36 (40%) 32 (38%)
Sick leave 3 (3%) 1 (1%)
Medical history 91 82
No cardiovascular history 37 (41%) 29 (35%)
Hypertension 27 (30%) 23 (28%)
Myocardial infarction 21 (23%) 28 (34%)
Heart failure 3 (3%) 7 (9%)
Cardiac arrest 1 (1%) 1 (1%)
CABG 8 (8%) 6 (7%)
Arrhythmia 8 (8%) 9 (10%)
Diabetes mellitus 14 (15%) 10 (12%)
Neurological history 8 (9%) 10 (12%)
Characteristics cardiac arrest
Cardiac cause 79 77 (98%) 81 77 (95%)
Location out-of-hospital 97 77 (79%) 88 70 (80%)
Witnessed cardiac arrest 95 89 (94%) 86 83 (97%)
Bystander CPR 92 83 (90%) 85 76 (89%)
Initial cardiac rhythm VF/VT 82 80 (98%) 77 71 (92%)
Time collapse — ROSC,
minutes
41 10 (0–70) 44 10 (0–60)
Duration coma, in days 63 1 (0–17) 58 2 (0–19)
Medical interventions 92 85
Therapeutic hypothermia 44 (48%) 38 (45%)
Catheterisation with PCI 41 (44%) 37 (44%)
CABG 10 (11%) 13 (15%)
ICD/pacemaker 21 (23%) 24 (22%)
Location of discharge 92 80
Home 80 (87%) 71 (89%)
Rehabilitation centre 7 (8%) 8 (10%)
Nursing home 5 (5%) 1 (1%)
Baseline functioning at 2 weeks
LVEF at discharge, % 31 44 (10–67) 32 44 (20–60)
NYHA classiﬁcation 83 84
1 35 (42%) 34 (41%)
2 31 (37%) 38 (45%)
3 9 (11%) 7 (8%)
4 8 (10%) 5 (6%)
Barthel Index 84 18.12 (3.61) 82 18.63 (3.02)
CABG = coronary artery bypass graft; CPR = cardiopulmonary resuscitation; VF =
ventricular ﬁbrillation; VT = ventricular tachycardia; ROSC = return of spontaneous cir-
culation; PCI = percutaneous coronary intervention; ICD = implantable cardioverter de-
ﬁbrillator; LVEF= left ventricular ejection fraction; NYHA=New York Heart Association.
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control group (p = 0.006). But there was no signiﬁcant difference in
employment status at 12 months: 32 people (74%) in the intervention
group and 27 people (71%) in the control group (p = 0.734) had
returned to work.
We did not ﬁnd any signiﬁcant effects on the outcomemeasures for
the caregivers (Table 5). Per protocol analyses found similar results as
intention to treat analyses.3.3. Success of blinding
Research assistants answered the question about group allocation
for 134 of the 143 patients who completed the trial. They answered cor-
rectly in 71 cases (53%), incorrectly in 33 cases (25%) and ‘I don't know’
in 29 cases (22%).4. Discussion
Cardiac arrest survivors who received our new early intervention
had an improved quality of life, a better overall emotional state and
less anxiety compared with thosewho only received the usual care. Ad-
ditionally, people in the intervention group seemed to return to work
more rapidly, a ﬁnding which could also have socio-economic impor-
tance. Improvements were both statistically signiﬁcant and clinically
relevant, indicating that our compact intervention does indeed have
the potential to increase functional outcome and quality of life for survi-
vors of a cardiac arrest. To the best of our knowledge, this is the ﬁrst
study to report such results.
What distinguishes our intervention from existing interventions is
the speciﬁc attention given to potential cognitive impairments. Al-
though cognitive impairments are common after a cardiac arrest, pa-
tients are often unaware of these brain-injury-related consequences,
and health care professionals alsomay not recognise these so-called ‘in-
visible’ problems [10]. To our knowledge, this is the ﬁrst intervention to
integrate active screening for possible cognitive problems into a psycho-
social and evidence-based intervention for survivors of a cardiac arrest
and their caregivers. The effectiveness of the intervention can probably
not be attributed to self-management as our process evaluation found
that this was rarely taught [14].
This study had several strengths. First, it had a broad population,
including patients of all ages who suffered both out-of-hospital and
in-hospital cardiac arrests, and who did or did not have an ICD. This
increases the generalisability of our results. Secondly, since we have al-
ready shown that this intervention is feasible, implementation in regu-
lar health care is therefore possible [14]. The fact that our intervention is
brief makes it attractive for future implementation, as costs will proba-
bly be low.
This study had some issues related to sample size. First, we did not
reach the target sample size of 168 participants, as only 143 of the 185
participants who enrolled in the trial completed it. Second, we adapted
the level of signiﬁcance from0.05 (one-sided), asmentioned in the orig-
inal protocol, to 0.01 (two-sided) in order to account for multiple test-
ing [12]. As a consequence, the original sample size calculation is not
in accordance with our actual statistical analysis. Therefore, we have
now checked the effect sizes that can be detected with our actual sam-
ple size and used the adapted signiﬁcance level. With the current num-
ber of participants (intervention group n = 76, control group n = 67),
using an alpha of 0.01 and a power (1− β) of 0.8, a standardised effect
size (Cohen's d) of 0.58 can be detected with the independent-samples
t-test. This indicates that medium effect sizes can be detected with our
current sample.
We used linear mixed models for the ﬁnal analyses, which resulted
in power gain over the independent-samples t-test. This occurred be-
cause it takes differences in baseline scores into account and uses all
available data, which means that data from patients who drop out are
also used in the analysis. The fact that clinically relevant improvements
on several important outcome measures were also found to be statisti-
cally signiﬁcant indicates that the study was sufﬁciently powered.
This study also had some limitations. First, the patients who refused
to participatewere somewhat older andmore often female. Elderly peo-
plemay bemore hesitant to participate in a study because of fears that it
will be burdensome. The greater number of femaleswho refused partic-
ipation may be related to this age difference as women, on average, live
longer thanmen. However, since the distribution of gender and agewas
Table 4
Patient outcomes and effect of the intervention.
Intervention Control Estimated mean difference Standard error p-Value
Observed mean (SD) Observed mean (SD)
Primary outcomes
Participation
Community Integration Questionnaire
– Premorbid 15.59 (4.77) 16.17 (4.34)
– 3 months 13.99 (4.79) 13.70 (5.47) 0.21 0.73 0.770
– 12 months 16.16 (4.68) 14.60 (5.16) 1.19 0.63 0.062
Quality of life
SF-36 Physical Functioning
– Baseline 59.16 (28.44) 54.11 (26.00)
– 3 months 73.44 (25.69) 69.71 (25.46) 1.87 3.24 0.565
– 12 months 78.47 (25.03) 73.05 (27.37) 4.59 3.71 0.218
SF-36 Social Functioning
– Baseline 54.55 (28.31) 52.56 (28.37)
– 3 months 71.05 (25.18) 70.96 (24.67) −0.58 3.99 0.885
– 12 months 81.77 (21.08) 79.88 (23.21) 2.95 3.61 0.416
SF-36 Role Physical
– Baseline 23.46 (33.85) 23.77 (34.21)
– 3 months 42.67 (41.26) 33.09 (40.39) 9.76 6.49 0.135
– 12 months 66.90 (41.36) 59.61 (43.23) 7.95 6.93 0.253
SF-36 Role Emotional
– Baseline 52.19 (44.00) 56.91 (42.39)
– 3 months 69.66 (42.02) 62.75 (44.06) 8.26 6.73 0.221
– 12 months 84.04 (32.30) 69.27 (41.70) 16.38 5.84 0.006
SF-36 Mental Health
– Baseline 71.51 (22.13) 73.90 (19.29)
– 3 months 76.21 (19.26) 76.81 (18.68) 0.59 2.38 0.805
– 12 months 81.35 (14.78) 76.06 (17.27) 6.87 2.25 0.003
SF-36 Vitality
– Baseline 56.65 (24.48) 56.95 (23.08)
– 3 months 64.04 (19.87) 64.42 (19.66) 0.54 2.55 0.831
– 12 months 65.83 (19.41) 62.23 (19.94) 5.07 2.70 0.063
SF-36 Bodily Pain
– Baseline 58.55 (27.74) 57.77 (29.97)
– 3 months 76.45 (24.38) 71.13 (26.46) 6.58 3.78 0.084
– 12 months 86.03 (21.29) 76.69 (26.16) 9.46 3.86 0.016
SF-36 General Health
– Baseline 56.95 (20.93) 61.22 (19.68)
– 3 months 60.06 (23.36) 61.32 (20.44) 2.63 2.56 0.305
– 12 months 64.79 (22.35) 60.00 (22.04) 8.07 3.08 0.010
EuroQol VAS
– Baseline 61.01 (18.91) 61.18 (18.62)
– 3 months 70.95 (17.06) 71.30 (15.95) −0.25 2.33 0.915
– 12 months 75.90 (16.50) 74.32 (14.45) 1.76 2.31 0.447
Secondary outcomes
Cognitive functioning
Cognitive Log
– Baseline 26.39 (3.43) 26.04 (3.28)
– 3 months 26.81 (3.06) 27.18 (2.43) −0.53 0.38 0.167
– 12 months 27.24 (2.58) 27.27 (2.64) −0.08 0.37 0.833
AMIPB task A
– Baseline 27.44 (10.70) 28.30 (9.65)
– 3 months 30.47 (9.84) 30.97 (9.49) −0.15 0.91 0.874
– 12 months 31.61 (10.07) 32.48 (9.84) 0.05 1.05 0.961
Verbal ﬂuency
– Baseline 19.41 (6.56) 18.86 (6.35)
– 3 months 21.05 (7.67) 21.81 (6.34) −1.40 0.80 0.082
– 12 months 22.50 (7.49) 23.33 (6.99) −1.28 0.94 0.175
Trail Making Test Aa
– Baseline 46.51 (32.63) 47.23 (21.60)
– 3 months 41.89 (24.60) 45.75 (26.38) 0.38 2.36 0.873
– 12 months 44.96 (32.75) 41.97 (24.84) 5.13 3.21 0.113
Trail Making Test Ba
– Baseline 123.83 (104.52) 129.48 (93.49)
– 3 months 112.71 (89.62) 111.11 (65.56) 0.35 7.29 0.962
– 12 months 103.26 (92.75) 109.08 (73.28) −10.53 6.79 0.124
Paragraph recall direct
– Baseline 6.61 (3.37) 6.34 (2.72)
– 3 months 7.01 (3.46) 7.49 (2.95) −0.64 0.42 0.132
– 12 months 6.84 (3.02) 7.03 (2.96) −0.19 0.41 0.633
Paragraph recall delayed
– Baseline 4.88 (3.14) 4.39 (2.56)
– 3 months 5.99 (3.79) 6.41 (3.10) −0.82 0.45 0.069
(continued on next page)
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Table 4 (continued)
Intervention Control Estimated mean difference Standard error p-Value
Observed mean (SD) Observed mean (SD)
– 12 months 5.27 (3.17) 5.70 (2.81) −0.61 0.40 0.130
Secondary outcomes
Cognitive functioning
Cognitive Failures Questionnairea
– Baseline 24.70 (15.38) 22.55 (13.94)
– 3 months 26.25 (16.32) 22.66 (14.68) 2.28 1.79 0.205
– 12 months 25.20 (15.14) 26.48 (15.57) −1.31 1.99 0.513
Emotional state
HADS Totala
– Baseline 10.13 (8.79) 9.27 (7.87)
– 3 months 8.32 (7.11) 7.42 (6.73) 0.20 0.92 0.827
– 12 months 5.74 (6.02) 8.22 (7.50) −3.25 1.02 0.002
HADS Anxietya
– Baseline 5.33 (5.09) 4.62 (4.14)
– 3 months 3.99 (3.53) 4.25 (3.80) −0.69 0.49 0.157
– 12 months 2.83 (3.06) 4.18 (4.06) −1.79 0.54 0.001
HADS Depressiona
– Baseline 4.83 (4.34) 4.64 (4.45)
– 3 months 4.33 (4.13) 3.27 (3.40) 0.87 0.53 0.103
– 12 months 2.90 (3.46) 4.03 (4.07) −1.36 0.58 0.020
Impact of Event Scalea
– Baseline 18.39 (18.07) 19.11 (15.28)
– 3 months 19.21 (18.39) 15.17 (15.40) 3.83 2.07 0.066
– 12 months 11.81 (14.56) 16.78 (16.31) −4.18 2.27 0.068
Extended daily activities
Frenchay Activity Index
– Premorbid 26.48 (7.51) 26.35 (7.44)
– 3 months 23.15 (9.63) 22.71 (9.70) 0.32 1.22 0.794
– 12 months 26.02 (8.60) 25.89 (8.47) −0.76 1.05 0.472
AMIPB = Adult Memory and Information Processing Battery; HADS = Hospital Anxiety and Depression Scale.
The bold-faced values indicate values which have a signiﬁcant p-value (p≤0.01)
a Outcome measures on which lower scores indicate better functioning.
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affected the results.
A second limitation is that the research assistants were not success-
fully blinded in all cases. Althoughwe instructed the research assistants
to do their best to ensure participants did not reveal their group assign-
ment, this was sometimes spontaneously disclosed during home visits.
However, as the research assistants were not involved in the data anal-
yses and did not have any other conﬂicts of interest, we do not expect
this have biased the study's results.
Some other points are worth discussing. Anxiety and depression
are acknowledged risk factors for new cardiac events and mortality
in patients after myocardial infarction [34,35]. The ﬁnding that this
intervention improved overall emotional state and lowered anxiety
may therefore have an additional positive effect on cardiovascular
prognosis. To investigate this, long-term follow-up would be
required.
Another important ﬁnding was that caregivers showed even more
symptoms of anxiety, depression and posttraumatic stress than the pa-
tients did, which conﬁrms that caregivers are at high risk for emotional
problems. However, this intervention did not result in signiﬁcant im-
provements for the caregivers. A review of the literature on family
members of patients who had been admitted to intensive care units
also found that further research is needed to determine how to reduce
the negative consequences for the family members [36]. Therefore, it
is essential to investigate what additional needs caregivers have and
to identify risk factors [37].
The costs of this intervention are relatively low. Societal gain is ex-
pected, as it seems to improve long-term quality of life and accelerate
the patient's return to work. However, cost-effectiveness analyses will
be subject of a separate analysis (to be reported).
To conclude, this study described an effective and feasible early
intervention that improved patient's quality of life and emotional
state after cardiac arrest, and resulted in a more rapid return towork. Our ﬁndings indicate that health care professionals should
not only address the cardiac consequences of a cardiac arrest, but
must also consider brain-related consequences. Future efforts should
therefore focus on making this additional care available to all cardiac
arrest survivors.
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Table 5
Caregiver outcomes and effect of the intervention.
Intervention Control Estimated mean difference Standard error p-Value
Observed mean (SD) Observed mean (SD)
Quality of life
SF-36 Physical Functioning
– Baseline 82.63 (23.06) 81.11 (21.55)
– 3 months 84.39 (22.27) 84.91 (18.67) −2.45 1.97 0.216
– 12 months 85.00 (19.46) 82.84 (21.27) 1.96 2.19 0.372
SF-36 Social Functioning
– Baseline 64.10 (28.37) 64.29 (28.50)
– 3 months 78.86 (23.88) 79.09 (21.79) −0.33 3.82 0.932
– 12 months 87.30 (17.60) 83.00 (21.69) 2.81 3.44 0.416
SF-36 Role Physical
– Baseline 63.61 (40.79) 60.21 (44.03)
–3 months 72.79 (40.23) 76.79 (34.99) −8.33 5.78 0.152
– 12 months 79.84 (35.60) 77.55 (36.17) 1.48 6.13 0.809
SF-36 Role Emotional
– Baseline 52.50 (44.93) 50.00 (47.14)
– 3 months 67.65 (42.70) 67.86 (41.18) −3.38 6.95 0.628
– 12 months 86.02 (31.68) 79.74 (33.39) 3.28 5.70 0.567
SF-36 Mental Health
– Baseline 60.68 (19.42) 57.63 (24.77)
– 3 months 72.46 (17.92) 74.57 (19.79) −2.59 2.80 0.357
– 12 months 80.06 (14.48) 75.92 (17.50) 2.16 2.60 0.406
SF-36 Vitality
– Baseline 54.81 (21.92) 53.59 (22.57)
– 3 months 65.80 (19.19) 63.30 (22.79) 2.03 2.96 0.493
– 12 months 70.97 (17.10) 64.61 (21.70) 4.66 2.98 0.121
SF-36 Bodily Pain
– Baseline 79.46 (23.14) 77.13 (23.94)
– 3 months 77.23 (22.17) 77.69 (20.93) −1.89 3.07 0.539
– 12 months 82.19 (21.20) 79.67 (24.07) 2.06 3.77 0.585
SF-36 General Health
– Baseline 64.81 (18.66) 67.07 (20.95)
– 3 months 69.93 (17.85) 68.48 (20.04) 3.76 2.33 0.110
– 12 months 69.35 (18.34) 68.27 (22.40) 2.91 2.90 0.317
EuroQol VAS
– Baseline 76.03 (15.22) 75.83 (16.01)
– 3 months 78.76 (13.39) 76.70 (18.19) 2.59 2.29 0.261
– 12 months 81.69 (15.02) 77.12 (16.70) 4.56 2.60 0.082
Caregiver strain
Caregiver Strain Indexa
– Baseline 5.15 (3.55) 4.87 (3.37)
– 3 months 3.32 (2.85) 4.21 (3.53) −0.43 0.45 0.348
– 12 months 2.74 (3.01) 3.25 (2.97) −0.12 0.45 0.786
Emotional state
HADS Totala
– Baseline 14.99 (9.57) 15.26 (10.49)
– 3 months 10.25 (8.80) 9.79 (8.70) 0.56 1.28 0.664
– 12 months 8.11 (7.18) 7.59 (6.62) 0.98 1.09 0.372
HADS Anxietya
– Baseline 8.55 (5.05) 8.79 (5.48)
– 3 months 6.29 (4.84) 5.86 (4.47) 0.43 0.69 0.530
– 12 months 5.02 (4.05) 4.83 (4.20) 0.68 0.62 0.280
HADS Depressiona
– Baseline 6.50 (4.97) 6.43 (5.45)
– 3 months 3.91 (4.32) 3.89 (4.74) 0.12 0.66 0.860
– 12 months 3.10 (3.62) 3.04 (3.30) 0.20 0.58 0.723
Impact of Event Scalea
– Baseline 32.39 (15.62) 32.59 (16.14)
– 3 months 24.92 (17.55) 22.08 (16.19) 2.49 2.34 0.288
– 12 months 21.20 (17.07) 19.87 (17.82) 2.42 2.23 0.279
HADS = Hospital Anxiety and Depression Scale.
a Outcome measures on which lower scores indicate better functioning.
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